Chronic progressive extern al ophthalmoplegia (CPEO) is caused by a decreased oxidative phosphorylation (OXPHOS) activity due to large-scale deletions of the mitochondrial genome in 50 % of the patients. The deletions encompass structural OXPHOS genes as weil as tRNA genes, required for their expression so that the pathogenesis could be due to the deleted OXPHOS subunits or to an impaired mitochondrial translation. We have analyzed the mitochondrial genome of a patient presenting with CPEO for single base substitutions and discovered a novel heteroplasmic mutation in the tRNAA,n gene at position 5692 that converts a highly conserved adenine into a guanine. This mutation is unique because it is located at the transition of the anticodon loop to the anticodon stern and it leads to an additional base pair, thus reducing the number of loop-forming nucleotides from seven to five. Our findings suggest that CPEO can be caused by a single base substition in a mitochondrial tRNA gene so that the mitochondrial protein synthesis becomes the rate limiting step in OXPHOS fidelity.
of patient' s symptoms varies, consistent with a mitotic or meiotic segregation of a heteroplasmic mutated mtDNA. FinaHy, as the patient's mitochondrial ATP-generating capacity declines, tissues of the central nervous system, skeletal muscle and heart are progressively affected, indicating that tissue-specific energetic thresholds are being traversed by the shift of heteroplasmy towards mutated mitochondrial DNA (8) . Genetically, the OXPHOS system is expressed under the combined control of the nuclear and the mitochondrial genome (7) that codes for seven subunits of complex I (NADH-ubiquinol oxidoreductase), one subunit of complex III (ubiquinol-cytochrome c oxidoreductase), three subunits ofcomplex IV (cytochrome c oxidase) and two subunits of complex V (ATP synthase). Additionally, it harbors the 12 Sand 16 S rRNA genes, as weH as a set of 22 tRNAs, required for the expression of the OXPHOS genes. Detailed RFLP-analyses of patients with CPEO revealed heteroplasmic length variations of the mitochondrial genome (1, 9, 10) . The most frequent "common deletion" spans 4977 bps, covering genes for complex I, IV and V as weH as tRNA genes for glycine, arginine, histidine, serine and leueine (1, 11) . Thus, the pathogenicity of mtDNA deletions causing CPEO could be due to three different processes: first, the deletion encompasses structural OXPHOS genes, so that depending on the degree of heteroplasmy within single mitochondria, deleted OXPHOS subunits cannot be synthesized (homoplasmic deleted genomes) or will be synthesized not in the required stoichiometries. Second, deletions generate fusion genes, so that expressed chimeric OXPHOS proteins could interfere with the assembly and functioning of the complexes. Third, besides the structural OXPHOS genes, the deletions always comprise essential tRNA genes. As a result of deleted genomes within single mitochondria, a decreased protein synthesis rate could cause the described OXPHOS deficiencies in patients with CPEO. Compatible with the latter described pathogenicity of mtDNA deletions is the recent observation that the mitochondrial tRNA Leu mutation at nucleotide pair 3243, previously attributed to cause mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), can be associated with progressive external ophthalmoplegia (PEO) (12) . In fact, it has been demonstrated that mutations in tRNA genes lead to an impaired mitochondrial protein synthesis in cultured cells of patients with myoclonic epilepsy and ragged-red fibers disease (MERRF) (13) and MELAS (14) .
This led us to the hypothesis that CPEO could be caused by yet unknown deleterious base substitution in mitochondrial genes essential for functional translation, mimicring adepleted • tRNA caused by a mtDNA deletion. Data presented in this paper support this speculation. By sequencing the mitochondrial genome of a patient presenting clinicaHy with CPEO (without length variation), we identified a novel heteroplasmic single base replacement that changes an A to a G in the anticodon loop of the tRN A Asn. This mutation, located near to the origin of light strand replication, converts a highly conserved nucleotide at position 5692 and was neither found in six unrelated caucasian controls nor in any other population studied so far (15) (16) (17) . Thus, the mutation eould aeeount for the pleiotropic phenotypie and biochemieal eharaeteristics associated with the disease.
MATERIALS AND METHODS

Patient.
The patient had ophthalmoplegia, muscle weakness of the lower limbs, a severe neuropathy, eerebellar signs and beginning eardiac dysfunction. Biochemieally, there was a :Slight reduetion of complexes I and IV of the respiratory chain. Histochemically, a few ragged-red fibers appeared on Gomori tri chrome staining.
Isolation of genomic DNA. Total DNA was prepared from about 100 mg of frozen muscle biopsy speeimens by the method of Seibel et al. (13) .
Southern hlot analysis. Two mierograms of total DNA were digested with Pvu 11 or Bam Hf, eleetrophoresed on a 0.5 % agarose gel and transferred onto nylon membranes (18) . The filters were hybridized to a random primer-extended probe generated from mtDNA isolated from human placenta.
Polymerase ehain reaetion. PCR was used to generate mitoehondrial DNA fragments for sequeneing and for the detection of mutated and wild-type mtDNA by RFLP analysis (19) . Asymmetrieally PCR-amplified DNA for dideoxynucleotide ehain-tenninating sequeneing was prepared by adding one primer in 100-fold excess of the other (molar ratio: 30 pmol : 0.3 pmol).
Primers used for amplijieation and sequencing. Forward DNA sequencing. Sequeneing primers were annealed to single-stranded DNA generated by asymmetrie PCR and segenced as described by Shoffner et al. (8) .
RFLP analysis. 500 ng of PCR-generated DNA amplified with the forward primer annealing to nt 4828-4848 and areverse primer located at nt 6266-6246 was purified by precipitation and digested with the restriction endonuclease Hpa f (10 units) for 3 h. The DNA fragments were resolved on a 1.2 % agarose gel and visualized by ethidium bromide staining under UV light.
Quantijication of heteroplasmie mtDNA. Heteroplasmic mtDNA was quantifieated by the modified method of Sei bel et al. (20) . After 25 cycles, peR was interrupted, supplemented with 32P-Iabeled dATP and restarted for an extra cycle, followed by Hpa J-RFLP analysis. DNA-fragments were exeised from an agarose gel and quantificated by counting the 32p radiation using a liquid seintillation counter.
RESULTS
Southern blot analysis of patient' s genomie DNA revealed no major length alteration (> 1.5 kb) of the mitochondrial genome, as the mtDNA formed only a single band of 16.5 kb in size.
Further restriction endonuclease mapping of the genomic DNA excluded also small mtDNA deletions (> 0.3 kb, data not shown). To study if any gene of the mitochondrial encoded translation apparatus was altered, the mitoehondrial genome of the patient was amplified in 11 fragments (eneompassing all tRNA and rRNA genes) and sequenced. A mutation was found at position 5692 (see fig. 1 a, left panel), almost 40 nucleotides upstream of the origin of light strand mtDNA replication. The mutation appeared heteroplasmically upon sequenee analysis. To determine if this mutation contributes to the pathogenieity of the disease, the same region was sequenced from a eontrol subject, whose DNA sequence revealed exclusively the wild-type adenine at this loeation (see fig. la, right panel) . This analysis was extended to additional patients and eontrols by utilizing the restrietion endonuclease Hpa I. This enzyme cleaves the wild-type sequenee (GTT AAC), while the mutated sequenee (GTT AGC) is not aItered. Hpa 1-RFLP analysis of PCR-generated DNA fragments resulted in fragments of 863 bp and 575 bp in ease of wild-type mtDNA, hut in an unaltered fragment of 1438 bp in the ease of the mutation. The patient's DNA was analyzed together with six unrelated eaueasian eontrols. While the patient's analysis revealed mutated and wild-type mtDNA (heteroplasmy), as expeeted from the sequenee analysis, the mutation was not found in the eontrols (see fig. 1 b) . Furthermore, the test failed to deteet the mutation in twelve unrelated CPEO patients without deletions. Using this test in a quantitative manner, the mitoehondrial genotype of the patient was estimated with about 56 % mutated and 44 % wild-type mtDNA.
To assess the funetional signifieanee of nucleotide pair 5692, we aligned the human tRNA Asn with the sequenees from other speeies (see fig. 2a ) relative to eonserved stem regions (21) . In • this alignment, the A was present in all other species from rat to sea urchin. Hence, nucleotide 5692 of the anticodon loop appears to be functionally conserved and its substitution could affect tRNA Asn function.
To iIlustrate how the function of the mutated tRNA could be affected, we studied the structural changes taking place in the anticodon loop of the mutated tRNA Asn. As was predicted by computer analysis (22) , the wild-type mttRNA Asn fonns a c1over-leaf structure with an anticodon loop of seven unmatched nuc1eotides. whereas its anticodon stern is formed by five base pairs (see fig. 2b ). The energy released during fonnation of stern and loop was estimated under standardized conditions [1 M Na-; pH = 7.0; T = 298.15 K] with -11.1 kllmol (23, 24) . The same analysis carried out for the mutated tRNA Asn led to a reorganization of the anticodon loop, as the mutated nucleotide fOlms now an additional hybrid pair with its counterpart. Therefore, the number of loop-forming nuc1eotides is decreased by two so that only five bases remain, whereas the stern is extended by an extra base pair. This results in an energy release of totally -30.5 kllmo!. As a consequence of the extra base pair formation, a further hybrid could be fOlll1ed by the next couple of bases (see fig. 2b ), leading to an extra extension of the stern by one base pair (total length: seven base pairs) so that only three bases remain to fOlm the anticodon loop. The energy release for this formation is estimated with -23.0 kllmo!.
DISCUSSION
The association of CPEO and KSS with large scale deletions of the mitochondrial genome has been reported before (1, 9, 10) . However, this accounts only for 50 % of the cases, the molecular basis of the others remains unclear, although an association of the MELAS mutation at nucleotide pair 3243 has been reported for patients with PEO (12) . The c1assical CPEO genotype (mtDNA deletion) results in a reduced OXPHOS activity. The pathogenic mechanism leading to the reduction is poorly understood and has been discussed controversely in the literature (25, 26) .
Most likely, the reduction of respiratory chain activity is due to the impaired mitochondrial translation rate caused by the deleted tRNA genes. If so, a mutation in a mitochondrial gene of the protein synthesis apparatus could result in a similar OXPHOS deficiency. Thus, we searched for a mutation in the mitochondrial genome of a patient with CPEO presenting no length variation that could explain similar pleiotropic phenotypic and biochemical alterations (biochemically: slightly reduced activity of complex I and IV, histochemically: ragged-red fibers). Only a single heteroplasmic nucleotide conversion was detected in this patient, which met all the criteria expected for a mutation causing CPEO: first, it is the only mutation in the sequenced tRNA and rRNA genes that alters a highly conserved element (see fig. 2a ). Second, it correlates perfectly with the disease: it was only found in the patient's genome and has not been found in our caucasian controls. is widely used in RFLP analysis and so far, a variation at mtDNA position 5692 has never been observed in any other population (15) (16) (17) . Third, it alters the tRNA in a way that could explain the decreased OXPHOS activity by a diminished mitochondrial protein synthesis rate. Fourth, it is heteroplasmic, consistent with arecent origin for a mutation. The shift from wild-type to almost complete mutated mtDNA takes place by the slow mechanism of mitotic or meiotic segregation (27) . The time required to enforce the mutation to homoplasmy is about four generations (Seibel, unpublished data, estimated from the tRNA Leu mutation at nucleotide pair 3243, previously attributed to MELAS). Thus, the tRNA Asn mutation at position 5692 fuHiIIs all the criteria predicted for a deleterious mutation and hence is most likely associated with the disease. Furthellnore, our findings support the hypothesis that diverse, yet unknown mutations in genes functioning in mitochondrial protein synthesis could contribute to the pathogenicity of CPEO in other cases as weIl.
The mechanism, how the mutation leads to a decreased respiratory chain activity as a result of an impaired translation, is unclear. Most likely, the secondary structure of the mitochondrial tRNA Asn is altered so that the tertiary structure of the anti co don loop is displaced. Following thermodynamic rules, systems always try to reach the lowest level of energy. Thus, the predicted tRNA Asn structure containing five anticodon loop-forming nucleotides is favoured during the formation process of the tRNA. The energy released during this process (dO o = -30.4 kJ/mol) is almost identical to the amount of energy released during the hydrolysis of ATP to ADP and phosphate (dO o = -30.5 kJ/mo!), indicating the stability ofthe formed loop-stem-structure. Thus, inhibition of assembly of the ribosome-mRNA-tRNA-complex required for a functional translation could be easily explained by the novel tertiary structure of the mutated tRNAA,n.
Other pathogenic mechanisms, however, as for instance an incorrect processing of the primary mitochondrial transcript, a malfunctioning modification or editing of tRNA bases, or an incorrect or inhibited loading of the tRNA by the aminoacyl-tRNA-synthetase cannot be excIuded.
Analysis ofthe mitochondrial genes required for functional translation showed that CPEO could be caused by a single base substitution. This observation suggests that mtDNA deletions causing similar c1inical phenotyps may be based on the same pathogenic mechanism. Hence, it is important to consider other yet undiscovered mutations in mitochondrial tRNA or rRNA genes as potential contributors to the pathogenesis of CPEO and related neuromuscular disorders.
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